In the last trading session, 1.25 million CervoMed Inc (NASDAQ:CRVO) shares changed hands as the company’s beta touched -0.32. With the company’s per share price at $11.08 changed hands at -$0.16 or -1.42% during last session, the market valuation stood at $96.43M. CRVO’s last price was a discount, traded about -133.94% off its 52-week high of $25.92. The share price had its 52-week low at $1.80, which suggests the last value was 83.75% up since then. When we look at CervoMed Inc’s average trading volume, we note the 10-day average is 1.82 million shares, with the 3-month average coming to 4.69 million.
Analysts gave the CervoMed Inc (CRVO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRVO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. CervoMed Inc’s EPS for the current quarter is expected to be -0.62.
CervoMed Inc (NASDAQ:CRVO) trade information
Instantly CRVO was in red as seen at the end of in last trading. With action 16.88%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 373.50%, with the 5-day performance at 16.88% in the green. However, in the 30-day time frame, CervoMed Inc (NASDAQ:CRVO) is 415.35% up. Looking at the short shares, we see there were 2.63 million shares sold at short interest cover period of 0.23 days.
The consensus price target for the stock as assigned by Wall Street analysts is 16.32, meaning bulls need an upside of 32.11% from its current market value. According to analyst projections, CRVO’s forecast low is 16.32 with 19.29 as the target high. To hit the forecast high, the stock’s price needs a -74.1% plunge from its current level, while the stock would need to soar -47.29% for it to hit the projected low.
CervoMed Inc (CRVO) estimates and forecasts
Year-over-year growth is forecast to reach -42.36% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 1.96M. 5 analysts are of the opinion that CervoMed Inc’s revenue for the current quarter will be 1.75M. The company’s revenue for the corresponding quarters a year ago was 2.35M and 3.29M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -16.41%. The estimates for the next quarter sales put growth at -46.68%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 56.66%. The 2025 estimates are for CervoMed Inc earnings to increase by 5.03%, but the outlook for the next 5-year period is at 3.71% per year.
CRVO Dividends
CervoMed Inc is expected to release its next quarterly earnings report on 2025-Mar-16.
CervoMed Inc (NASDAQ:CRVO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 33.38% of CervoMed Inc shares while 17.21% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 25.84%. There are 17.21% institutions holding the CervoMed Inc stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 9.3892% of the shares, roughly 0.82 million CRVO shares worth $13.99 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 7.354% or 0.64 million shares worth $10.96 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 255.64 shares estimated at $2.83 million under it, the former controlled 2.94% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.47% of the shares, roughly 127.55 shares worth around $1.41 million.
